Perrigo Company plc (PRGO)
NYSE: PRGO · Real-Time Price · USD
25.34
+0.10 (0.40%)
Feb 21, 2025, 4:00 PM EST - Market closed
Perrigo Company Revenue
Perrigo Company had revenue of $1.09B in the quarter ending September 28, 2024, a decrease of -3.23%. This brings the company's revenue in the last twelve months to $4.39B, down -5.63% year-over-year. In the year 2023, Perrigo Company had annual revenue of $4.66B with 4.58% growth.
Revenue (ttm)
$4.39B
Revenue Growth
-5.63%
P/S Ratio
0.79
Revenue / Employee
$480,525
Employees
9,140
Market Cap
3.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 4.66B | 204.00M | 4.58% |
| Dec 31, 2022 | 4.45B | 312.90M | 7.56% |
| Dec 31, 2021 | 4.14B | 50.50M | 1.24% |
| Dec 31, 2020 | 4.09B | 218.30M | 5.64% |
| Dec 31, 2019 | 3.87B | -861.80M | -18.21% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Jun 27, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
PRGO News
- 3 days ago - Perrigo Increases Quarterly Dividend by 5% - PRNewsWire
- 18 days ago - Opill® extends mission of breaking down birth control barriers with launch of multi-state college tour and expansion of partnerships - PRNewsWire
- 22 days ago - Perrigo to Release Fourth Quarter and Fiscal Year 2024 Financial Results on February 27, 2025, Host Virtual Investor Day on February 28, 2025 - PRNewsWire
- 25 days ago - Perrigo Paves The Way For Recovery With Margin Focus - Seeking Alpha
- 6 weeks ago - Perrigo Expands its Scientific Office; Appoints Abbie Lennox as Executive Vice President and Chief Scientific Officer - PRNewsWire
- 3 months ago - Perrigo Company: Great Combination Of Future Growth With A Low Valuation - Seeking Alpha
- 3 months ago - Perrigo Company plc (PRGO) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Perrigo Reports Third Quarter 2024 Financial Results From Continuing Operations - PRNewsWire